Alpha 2.0
Login Register
» Articles » PMID: 38596202

Can the ADO Index Be Used As a Predictor of Mortality from COVID-19 in Patients with COPD?

Overview
Journal Int J Chron Obstruct Pulmon Dis
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2024 Apr 10
PMID 38596202
Authors
Esra Ertan Yazar
Gulsah Gunluoglu
Burcu Arpinar Yigitbas
Mukadder Calikoglu
Gazi Gulbas
Nilgun Yilmaz Demirci
Nurhan Sarioglu
Fulsen Bozkus
Nevin Taci Hoca
Nalan Ogan
Seda Tural Onur
Muzaffer Onur Turan
Filiz Kosar
Evrim Eylem Akpinar
Burak Mete
Can Ozturk
Affiliations
Soon will be listed here.
Abstract

Background: Several studies have shown that the risk of mortality due to COVID-19 is high in patients with COPD. However, evidence on factors predicting mortality is limited.

Research Question: Are there any useful markers to predict mortality in COVID-19 patients with COPD?.

Study Design And Methods: A total of 689 patients were included in this study from the COPET study, a national multicenter observational study investigating COPD phenotypes consisting of patients who were followed up with a spirometry-confirmed COPD diagnosis. Patients were also retrospectively examined in terms of COVID-19 and their outcomes.

Results: Among the study patients, 105 were diagnosed with PCR-positive COVID-19, and 19 of them died. Body mass index (p= 0.01) and ADO (age, dyspnoea, airflow obstruction) index (p= 0.01) were higher, whereas predicted FEV (p< 0.001) and eosinophil count (p= 0.003) were lower in patients who died of COVID-19. Each 0.755 unit increase in the ADO index increased the risk of death by 2.12 times, and each 0.007 unit increase in the eosinophil count decreased the risk of death by 1.007 times. The optimum cut-off ADO score of 3.5 was diagnostic with 94% sensitivity and 40% specificity in predicting mortality.

Interpretation: Our study suggested that the ADO index recorded in the stable period in patients with COPD makes a modest contribution to the prediction of mortality due to COVID-19. Further studies are needed to validate the use of the ADO index in estimating mortality in both COVID-19 and other viral respiratory infections in patients with COPD.

References
1.
Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D . Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021; 9(8):909-923. PMC: 8016404. DOI: 10.1016/S2213-2600(21)00095-3. View
2.
Rabbani G, Islam S, Rahman M, Amin N, Marzan B, Robin R . Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. Expert Rev Respir Med. 2020; 15(5):705-716. DOI: 10.1080/17476348.2021.1866547. View
3.
Gerayeli F, Milne S, Cheung C, Li X, Yang C, Tam A . COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 33:100789. PMC: 7971471. DOI: 10.1016/j.eclinm.2021.100789. View
4.
Schultze A, Walker A, Mackenna B, Morton C, Bhaskaran K, Brown J . Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8(11):1106-1120. PMC: 7515601. DOI: 10.1016/S2213-2600(20)30415-X. View
5.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View